United States Health

American Healthcare REIT (NYSE:AHR) acquired eight Class A senior housing communities for approximately $696 million, expanding its presence in East Coast senior housing markets.

HUTCHMED (NASDAQ:HCM) signed an exclusive development and license agreement with a GSK subsidiary for HMPL-A830, a KRAS-EGFR Antibody-Targeted Therapy Conjugate, covering worldwide rights outside Mainland China, Hong Kong, Macau, and Taiwan.

United Therapeutics Corporation (NASDAQ:UTHR) announced that the FDA accepted its supplemental New Drug Application for nebulized Tyvaso (treprostinil) Inhalation Solution as a potential treatment for idiopathic pulmonary fibrosis (IPF).

uniQure (NASDAQ:QURE) submitted a Biologics License Application to the U.S. FDA and a Marketing Authorisation Application to the U.K. MHRA for ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for Huntington’s disease.

Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline Phase 2a results for TEV ‘408, its investigational anti-IL-15 monoclonal antibody for adults with celiac disease following a gluten-free diet.

Aurora Cannabis (NASDAQ:ACB) recommended that shareholders reject Curaleaf Holdings’ unsolicited hostile takeover bid, advising investors not to tender their shares or withdraw any previously tendered shares.

Zepp Health (NYSE:ZEPP) reported second-quarter 2026 revenue of US$63.5 million, up 6.9% year over year, as the company recorded higher gross margins and expanded product activity.

Evotec (NASDAQ:EVO) and Plectonic Biotech have entered a research collaboration to evaluate a T-cell-engaging immunotherapy concept for solid tumors using their respective biotechnology platforms.

Biomerica (NASDAQ:BMRA) reported fiscal 2026 revenue of approximately $4.50 million, down from $5.30 million in fiscal 2025, while net loss improved to $3.8 million.

Alumis (NASDAQ:ALMS) reported Phase 2b LUMUS trial results for oral TYK2 inhibitor envudeucitinib in moderate-to-severe systemic lupus erythematosus, with the overall study population not meeting the primary endpoint.

Emergent BioSolutions (NYSE:EBS) received a contract modification valued at approximately $24 million from BARDA to supply CYFENDUS anthrax vaccine for U.S. government preparedness programs.

Kazia Therapeutics (NASDAQ:KZIA) reported preclinical data showing its PI3K/mTOR inhibitor paxalisib reduced tumor burden by 52% in an MSS/pMMR colorectal cancer model.